公开(公告)号：US20160130315A1

公开(公告)日：2016-05-12

申请号：US14893317

申请日：2014-05-22

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Yong Sung KIM ,  Tae Hwan SHIN ,  Yae Jin KIM ,  Eun Sil SUNG

IPC: C07K14/47

CPC classification number: C07K14/4703 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

Abstract: A tumor tissue-penetrating peptide specifically binding to neuropilin, or a fusion protein, a small molecule drug, a nanoparticle, or a liposome having the peptide fused therein is provided, as well as a method for preparing the same and a pharmaceutical composition comprising the same for treating, diagnosing, or preventing cancer or angiogenesis-related diseases. The tumor tissue-penetrating peptide is fused to the C-terminus of an anticancer antibody heavy-chain constant region (Fc) and the fused antibody specifically binds to neuropilin, and specifically accumulates in tumor tissue, widens intercellular gaps between tumor vascular endothelial cells, promotes extravasation, increases infiltration within tumor tissue, and shows a remarkably increased in vivo tumor-suppressing activity. Furthermore, the tumor tissue-penetrating peptide is fused into a fusion protein and inhibits the angiogenic function of neuropilin coreceptors resulting from targeting of neuropilin, and is expected to have an alleviating effect on angiogenesis-related diseases.

Abstract translation: 提供了特异性结合神经纤维素的蛋白质组织穿透肽，或融合蛋白质，小分子药物，纳米颗粒或其中融合肽的脂质体，以及其制备方法和药物组合物，其包含 相同的治疗，诊断或预防癌症或血管生成相关疾病。 肿瘤组织穿透肽与抗癌抗体重链恒定区（Fc）的C末端融合，融合抗体特异性结合神经纤维蛋白，特异性地积聚在肿瘤组织中，扩大肿瘤血管内皮细胞之间的细胞间隙， 促进外渗，增加肿瘤组织内的浸润，并显示体内肿瘤抑制活性显着增加。 此外，将肿瘤组织穿透肽融合成融合蛋白，并抑制由神经丝氨酸靶向产生的神经丝氨酸共受体的血管生成功能，并且预期对血管发生相关疾病具有缓解作用。

公开(公告)号：US20190194715A1

公开(公告)日：2019-06-27

申请号：US16311161

申请日：2017-05-12

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Tae Hwan SHIN ,  Geetika PHUKAN ,  Man Jeong PAIK ,  Hyeon-Seong LEE ,  Hyung-Jin PARK ,  Da Yeon LEE ,  Gwang LEE

IPC: C12Q1/02 ,  C12Q1/6881 ,  C12Q1/6837

CPC classification number: C12Q1/025 ,  C12Q1/68 ,  C12Q1/6837 ,  C12Q1/6881 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/142 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: A method of assessing neurotoxicity of nanoparticles, includes: preparing a tissue or cell sample of mammal exposed to the nanoparticles; analyzing at least one polyamine metabolite selected from the group consisting of putrescine, N1-acetylspermidine, N8-acetylspermidine, N1-acetylspermine and spermine in the sample; and comparing expression degree of the polyamine metabolite with that of a control.